Humacyte Inc. (NASDAQ: HUMA) announced that its acellular tissue engineered vessel (ATEV) met the primary endpoint in an interim analysis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE